PRSS1 and neoplasm: To date, all known PRSS1 mutations are somatic, with genetic tendency and dominant traits, which is different from EGFR/KRAS/BRAF gene mutations present in the context of cancerous tissues; somatic mutations are an important causal factor of tumorigenesis and a critical element for tumor heterogeneity (Hezel et al., 2006; Chang et al., 2017; Le Maréchal et al., 2006).